Abstract
Benign paroxysmal positional vertigo (BPPV) is the most common peripheral vestibular disorder, arising from degeneration and displacement of otoconia from the utricular macula into the semicircular canals. Although diagnosis relies on clinical history and provocative positional maneuvers, it may be challenging when positional nystagmus is subtle or absent or when positional testing cannot be adequately performed. Otolin-1 and otoconin-90 (OC90), the two principal structural proteins of the otoconial matrix, can cross the blood-labyrinth barrier and can be detected and quantified in peripheral serum, making them candidate biomarkers of otoconial degeneration. This narrative review summarizes current evidence for otolin-1 and OC90 as diagnostic and prognostic biomarkers in BPPV. Across multiple case-control studies and one meta-analysis, serum otolin-1 has been consistently elevated in patients with BPPV compared with healthy controls, and may also be associated with disease severity and recurrence. In contrast, findings for OC90 have been inconsistent, with studies reporting increased, decreased, or unchanged levels in BPPV relative to controls. Despite these promising findings, substantial heterogeneity in laboratory methods, potential biological confounders, inconsistent timing of blood sampling, and the lack of comparisons with other vestibular disorders currently limit their clinical applicability. Standardized assays and well-designed prospective studies incorporating serial measurements and appropriate disease-control groups are needed to determine whether these proteins can serve as reliable and specific biomarkers for BPPV.

This publication has 29 references indexed in Scilit: